Find latest Colon Cancer videos
·
400+ videos
ASCO® GI 2025 Summary: Updates in Anal Cancer
By
Insights from 2025 ASCO® GI Annual Meeting
FEATURING
Cathy Eng
By
Insights from 2025 ASCO® GI Annual Meeting
FEATURING
Cathy Eng
Disclaimer: On May 15, 2025, the FDA has approved retifanlimab-dlwr (Zynyz) in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC). The FDA has also approved retifanlimab as monotherapy for the treatment of adult patients with locally recurrent or metastatic SCAC with disease progression on or intolerance to platinum-based chemotherapy.
Comments 0
Login to view comments.
Click here to Login
